Prevalence of Viral Hepatitis in Unselected, Consecutively Enrolled Patients Hospitalised for SARS-CoV-2

Silvia Dettori1,2 · Chiara Russo1,2,A,4 · Sara Mora3 · Mauro Giacomini3 · Lucia Taramasso2 · Chiara Dentone2 · Antonio Vena1,2 · Matteo Bassetti1,2 · Antonio Di Biagio1,2

Accepted: 30 May 2022 / Published online: 21 June 2022 © The Author(s) 2022

Abstract
Diagnosing people living with chronic viral hepatitis is challenging due to the absence of symptoms as long as liver decompensated cirrhosis come out. The aim of this retrospective study was to evaluate the prevalence of HBV and/or HCV infections in a non-selected population, hospitalised for SARS-CoV-2 infection in a tertiary care hospital in Northern Italy. During the study period 1,429 patients were admitted to hospital for SARS-CoV-2 infection, serologic tests for HBV and/or HCV were available for 382 (27%) patients and 3 were excluded due to their previous known serologic status. Among 379 patients, 235 (62%) were male, median age was 70 years (range 21–103), 360 (95%) were Caucasian. Among them, 372/379 (98%) were screened for HBsAg, 320/379 (84%) for HBcAb. HBsAg was positive in 2/372 (0.5%, 95% CI 0.0006–0.02) patients (only in one HBV-DNA was performed that was negative), while HBcAb was found positive in 55/320 (17%, 95% CI 0.13–0.22). Among 370/379 (98%) patients screened for HCV, 11/370 (3%, 95% CI 0.02–0.05) had positive HCV-Ab. Five out of 11 (45%) were tested for HCV-RNA that resulted positive in two patients (0.5%, 95% CI 0.0006–0.02). Considering this data, even though the screening was performed in only 27% of study population, a tailored screening in people with known risk factors for hepatitis might be preferable to universal screening in low prevalence areas. Also a prompt diagnostic workout should begin in case of clinical or laboratory suspicion of hepatitis and in those starting immunosuppressive treatments.

Keywords Viral hepatitis · Hepatitis screening · SARS-CoV-2 · Eradication

Introduction
Hepatitis B (HBV) and C (HCV) virus infections remain a significant cause of morbidity and mortality in the world [1]. The World Health Organization (WHO) estimates that in 2019, 1,500,000 new HBV infections and 1,500,000 new HCV infections occurred, with 820,000 and 290,000 HBV and HCV related deaths, respectively [1]. In the United States alone, the Center for Disease Control and Prevention (CDC) estimates 20,700 acute HBV infections and 57,500 acute HCV infections in 2019, with an incidence of 1.0 and 1.3 cases/100,000 people, respectively [2]. According to the CDC, the most affected groups are people aged 40–49 years, males, white non-Hispanics and injecting drug users (IDU) [2]. The Polaris Observatory, the authoritative resource for epidemiological data for HBV and HCV, estimates that 71 million people are infected with HCV globally and approximately 400,000 people/year die from causes related to HCV [3].
In Italy, the epidemiology system for surveillance of viral acute hepatitis SEIEVA (coordinated by the Italian Superior Health Institute) reported an incidence of 0.21 and 0.04 cases/100,000 inhabitants for acute HBV and HCV hepatitis in 2020 [4]. These numbers confirm a trend in reduction of HBV and HCV incidence in Italy as compared to the past, as in 1985 the estimated incidence of HBV and HCV was 12 and 5 cases per 100,000 inhabitants [4]. Despite this, the true prevalence of chronic HBV and HCV infections in Italy as well as globally is still to be determined, and only estimations can be made at present. It is estimated that in 2020, 332,157 people were infected with HBV in Italy, of which only 29% have been diagnosed, while only 46% of the total cases have been treated, with 1,200 annual deaths related to HBV [5]. For HCV, it is estimated that 680,000 people were infected in 2020, of which only 60% have been diagnosed and only 5% of the total have been treated, with 11,236 annual deaths related to HCV [5].

In 2016, the WHO set the goal of eradication of viral hepatitis as a major public health objective. The specific goals are 90% of diagnosed infections, 80% of treated infections and 65% reduction of hepatitis-related mortality by 2030 [6].

Unfortunately, only 24% of 45 high-income countries are forecasted to reach the WHO elimination targets by 2020 and 62% by 2050 [7].

Strategies to improve the detection of unknown HBV and HCV infections are currently under investigation. To evaluate the prevalence of HBV and HCV in the general population and the possible utility of serologic screening tests for people accessing hospital services, we studied the seroprevalence of HBV and HCV in a non-selected population of patients hospitalised for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with Coronavirus disease 2019 (COVID-19) in a tertiary care hospital in Northern Italy.

Materials and Methods

This is a retrospective, single-centre study conducted in IRCCS San Martino Hospital, a 1200-bed tertiary care hospital in Genoa, Northern Italy. The study period was from 25th February 2020 to 31st January 2021.

All patients hospitalised for SARS-CoV-2 infection were consecutively included in the study if they were aged ≥ 18 years. Exclusion criteria were their known positive serological statuses for HBV or HCV. Data on sex, age, ethnicity, HBsAg and HBCAb, HCV-Ab, HCV-RNA and HBV-DNA were retrieved from MedInfo, an online database for anonymous and automatic data collection [8]. In addition, possible risk factors for HBV and HCV infections were collected, such as IDU or people born between 1945 and 1965, sometimes referred to as baby boomers [9], or exposure to transfusion or injection with glass syringes in the years between the 50s and the 80s [10].

The primary objective was to describe the prevalence of HBV and/or HCV infections in a non-selected population. The secondary objective was to evaluate the number of coinfections with HIV. We also evaluated if newly diagnosed patients were hospitalized and treated, and whether their progress was followed up on. Data are presented as prevalence with a 95% confidence interval (CI) calculated with a binomial test.

The collection of anonymized data for the study was approved by the Ethics Committee of the Coordinating Centre and specific informed consent was waived due to the retrospective nature of the study (registry number 163/2020, Liguria Region Ethics Committee).

Results

During the study period, 1429 patients were admitted to our hospital for SARS-CoV-2 infection. Serologic tests for HBV and/or HCV were available for 382 (27%) patients.

Three patients were excluded due to their known previous HCV positive serological statuses: two of them had been previously treated with Direct Acting Antivirals (DAA) and had concomitant HIV infection on antiretroviral treatment, while the third had a previous negative HCV-RNA status. Among them, 235 (62%) were male, the median age was 70 years (range 21–103), 360 (95%) were Caucasian (357 Italian), 17 (4%) Latin-American and 2 (0.5%) were from Africa and Asia.

HBV

Among patients with whom serologic tests were performed, 372/379 (98%) were screened for HBsAg and 320/379 (84%) for HBcAb. HBsAg was positive in 2/372 (0.5%, 95% CI 0.0006–0.02) patients, while HBcAb was found in 55/320 (17%, 95% CI 0.13–0.22) screened patients (Fig. 1). Neither of them was on anti-HBV treatment nor had chronic HCV or HIV infection (Table 1), and neither received specialist follow-ups.

HCV

Among patients with whom serologic tests were performed, 370/379 (98%) were screened for HBsAg and 320/379 (84%) for HBcAb. HBsAg was positive in 2/372 (0.5%, 95% CI 0.0006–0.02) patients, while HBcAb was found in 55/320 (17%, 95% CI 0.13–0.22) screened patients (Fig. 1). Among the two patients with HBsAg, HBV-DNA was negative in one patient and was not tested in the other. Neither of them was on anti-HBV treatment nor had chronic HCV or HIV infection (Table 1), and neither received specialist follow-ups.

Among patients with whom serologic tests were performed, 370/379 (98%) were screened for HBsAg and 320/379 (84%) for HBcAb. HBsAg was positive in 2/372 (0.5%, 95% CI 0.0006–0.02) patients, while HBcAb was found in 55/320 (17%, 95% CI 0.13–0.22) screened patients (Fig. 1). Among the two patients with HBsAg, HBV-DNA was negative in one patient and was not tested in the other. Neither of them was on anti-HBV treatment nor had chronic HCV or HIV infection (Table 1), and neither received specialist follow-ups.
Fig. 1  HBV and HCV screening performed and results.  Ab antibody, Ag antigen, pos positive

Table 1  Patients’ characteristics

| Patient | Age | Sex | Ethnicity | Medical history | HCV-RNA/HBV-DNA (UI/mL) | Risk factor for chronic hepatitis | Clinical follow-up/therapy |
|---------|-----|-----|-----------|-----------------|-------------------------|---------------------------------|--------------------------|
| Patient 1 | 67  | F   | Caucasian | Ex smoker, previous appendicectomy | HCV-RNA 7.4 × 10⁶ | Age* | HCV positive serology since 2015, unknown to patient. Scheduled ambulatory follow-up, death for other cause before data of visit |
| Patient 2 | 60  | M   | Caucasian | Heart failure, atrial fibrillation, T2DM | HCV-RNA 6.4 × 10⁵ | Age* | HCV positive serology performed |
| Patient 3 | 71  | M   | Caucasian | Epilepsy, poliomyelitis, post-traumatic cerebral bleeding | Not done | Age* | Death the day after serology performed |
| Patient 4 | 103 | F   | Caucasian | T2DM, psoriasis | Not done | Age* | HCV positive serology since 2015, unknown to patient |
| Patient 5 | 85  | F   | Caucasian | Myocardial ischemia, CKD | Not done | Age* | Death 4 days after serology performed |
| Patient 6 | 54  | M   | Caucasian | Asthma, ex-IDU | Negative | IDU | None required |
| Patient 7 | 86  | M   | Caucasian | Atrial fibrillation, COPD, CKD | Negative | Age* | None required |
| Patient 8 | 80  | F   | Caucasian | COPD, T2DM, obesity | Not done | Age* | Death during a second hospitalization in June 2021 |
| Patient 9 | 84  | M   | Caucasian | Atrial fibrillation, heart failure, T2DM | Not done | Age* | Death during hospitalization |
| Patient 10 | 82  | M   | Caucasian | COPD, T2DM, alcohol abuse | Negative | Age* | HCV positive serology since 2014, unknown to patient |
| Patient 11 | 21  | F   | Caucasian | IDU, bipolar disorder | Not done | IDU | Lost to follow up |
| Patient 1 | 60  | M   | Caucasian | Hypertension, Ehler-Danlos syndrome and mitral prolapse, spinocellular carcinoma with lymph nodal metastasis | Not done | Age* | Death during hospitalization |

C⃝ Springer

*Age: people born between 1945 and 1965 or with possible exposure to transfusion or injection with glass syringes between 50s’ and 80s’
Discussion

Our study highlights a low prevalence of HBV and HCV in the study population (0.5% and 0.5%, 95% CI 0.0006–0.02, respectively).

We do not have data about HCV screening in the pre-COVID-19 era from our hospital, but we can assume that the frequency of screening during the study period was reduced compared to the past [11]. Conversely, in other areas of Northern Italy, the SARS-CoV-2 pandemic was thought to be exploited to increase HCV screening in the Italian population and achieve the WHO goal of HCV elimination [12].

Among patients with a positive HCV serology in our study population, five out of 11 showed severe clinical conditions, thus further investigations were not conducted. On the other hand, almost all HCV-Ab positive patients had anamnestic reports of medical visits or hospitalisations before the study was performed, and therefore had missed the opportunity for a previous diagnosis and eradication.

While analysing the patients’ characteristics, we found that more than half of HCV-Ab positive patients were aged > 60 years, according to the high prevalence of HCV in the second part of the twentieth century [2, 10], and about 20% were IDU, a known risk factor for HCV infection [2, 10].

Although the prevalence of chronic HBV and HCV is still unknown, some authors hypothesised that there is a high number of HCV infected individuals still undiagnosed in Italy [10]. Through a mathematical model, they estimated undiagnosed HCV to be about 281,809 individuals in October 2019 [10].

Even if extensive screening can reduce hospitalisation, costs and deaths related to chronic hepatitis [13], the perception based on our results is that the screening could be narrowed down to suit people with HCV infection risk factors, such as period of birth, drug abuse, blood transfusion and/or surgical procedure before the 90s [2, 10, 14]. In addition, it is important that patients with a new diagnosis of chronic HCV infection are referred to care [15].

Furthermore, the prevalence of chronic HBV infection was low in our study since only two patients had positive HBsAg, and we expected an even lower prevalence in people born in Italy after HBV vaccination became mandatory in 1990 [16].

Similar to HCV chronic hepatitis, we can assume that the screening for HBV was higher in the pre-pandemic period [17]. Moreover, a recent study conducted in the United States demonstrates that conducting HBV screenings for a population is cost-effective even when the estimated prevalence is low, because it can help to prevent chronic HBV infection complications [18].

Even when the prevalence of active chronic HBV infection was low, we found a high proportion of previous HBV infections with HBCAb positivity (about 20%). People with HBCAb positivity are at risk of reactivation of HBV infection when exposed to immunosuppressive therapies [19, 20]. As some immunosuppressive drugs used for COVID-19, like tocilizumab and baricitinib can lead to HBV reactivation [21], HBV screening should be offered with significant attention paid to patients eligible for these therapies, even though the risk appears to be low in patients with previous and resolved HBV infections [22]. Most data stems from studies about autoimmune diseases in which these medications were administered together with some other agents, such as high dose and prolonged corticosteroids therapy or other disease-modifying antirheumatic drugs (DMARDs) [23, 24]. In our study population, only 320/1429 (22%) patients potentially to be treated with immunosuppressive therapies were screened for HBCAb, a low percentage which was probably due to the pandemic era. However, even in an overworked period, clinicians should maintain diagnostic and therapeutic appropriateness. Nonetheless, not all patients with SARS-CoV-2 infections need immunosuppressive therapies, especially after the introduction of vaccination and outpatients’ therapies [25].

The first limitation of our study is that serology for HBV and/or HCV was tested in only 27% of patients admitted to the hospital for SARS CoV-2 infection in the study period. Furthermore, our study is retrospective and the seroprevalence screening of HBV and HCV chronic infection in the pre-pandemic era is unknown to us. The second limitation is that during the first wave of the COVID-19 pandemic, medical efforts were focused on COVID-19 instead of routine patient management and the best clinical approach. This could have also reduced the linkage of patients with a new diagnosis of chronic HBV and HCV hepatitis to care [26].

Yet another limitation is that 95% of patients were Caucasian, and only 0.5% were from Africa and Asia, a population with a higher prevalence of chronic HBV and HCV infection compared to Italy [27, 28].

Since the median age of our study population is 70 years, we conducted the screening on the population...
with the higher prevalence of chronic HBV and HCV infection in Italy (9, 10), and therefore we can assume that the prevalence of chronic viral hepatitis is low among the non-selected population.

In conclusion, diagnosing people living with chronic viral hepatitis is challenging due to the absence of symptoms other than liver decompensated cirrhosis. A tailored screening in people with known risk factors for hepatitis might be preferable to universal screening in low prevalence areas, even though prompt diagnostic workout should begin in case of clinical or laboratory suspicion of hepatitis and in those patients starting immunosuppressive treatments. Moreover, a targeted effort could give benefits on the linkage to care and epidemiological control and reduce the risk of losing patients to follow-up in a wide screening.

Nevertheless, our study reports the prevalence and not the incidence of HBV and HCV chronic hepatitis. Even if we think that a tailored screening should be preferred instead of a universal one, surveillance of chronic hepatitis should be performed to identify a possible trend reversal.

Acknowledgements The authors want to thank all members of GECOVIS study group.

Author Contributions Conceptualization was by SD, CR and AB, LT; methodology was by SD, CR, A, LT and AV. Experimental data were processed by SM and MG. The original draft was written by SD and CR; review and editing were by SD, CR, AB, LT, CD, AV, MB. AB and LT supervised the study.

Funding Open access funding provided by Università degli Studi di Genova within the CRUI-CARE Agreement. Not applicable.

Data Availability Anonymized data available to all.

Code Availability Individual code available to all.

Declarations

Conflict of interest Outside the submitted work, LT received grants for consultancies by Viiv Healthcare and Gilead Sciences. CD received grants for advisory boards sponsored by Viiv Healthcare and speaker invitations by Gilead Sciences, MB has received funding for scientific advisory boards, travel, and speaker honoraria from Angelini, Astellas, Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, Shionogi, Tetraphase, Nabiriva. ADB has received funding for scientific advisory boards, travel, and speaker honoraria from Viiv Healthcare, Gilead, Janssen, Abbvie, MSD. The other authors declare no conflicts of interest.

Consent to Participate Waived due to the retrospective nature of the study.

Consent for Publication Waived due to the retrospective nature of the study.

Ethical Approval Registry number 163/2020, Liguria Region Ethics Committee.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Global progress report on HIV, viral hepatitis and sexually transmitted infections. (2021). WHO Global report. Retrieved from https://www.who.int/publications/i/item/9789240027077.
2. Centers for Disease Control and Prevention. Nation center for HIV, viral hepatitis, STD and TB prevention. Retrieved from https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm.
3. Polaris Observatory HCV Collaborators. (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. Lancet Gastroenterol Hepatol, 2(3), 161–176.
4. Epicentro, dati SEIEVA 31 dicembre 2020. Istituto Superiore di Sanità. Retrieved from https://www.epicentro.iss.it/epatite/dati-seieva.
5. CDA Foundation. Polaris Observatory. Retrieved from https://cdafound.org/polaris/.
6. Global health sector strategy on viral hepatitis 2016–2021. (2016). Towards ending viral hepatitis. World Health Organization. Retrieved from https://apps.who.int/iris/handle/10665/246177.
7. Razavi, H., Pawlotsky, J. M., Lazarus, J. V., et al. (2020) Global timing of hepatitis C virus elimination in high-income countries: an updated analysis. EASL Poster. Retrieved from https://www.natap.org/2020/EASL/EASL_06.htm.
8. Fraccaro, P., Pupella, V., Gazzarata, R., et al. (2013). The ligurian human immunodeficiency virus clinical network: A web tool to manage patients with human immunodeficiency virus in primary care and multicenter clinical trials. Medicine 2.0, 2(2), e5.
9. Smith, B. D., Morgan, R. L., Beckett, G. A., et al. (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. Morbidity and Mortality Weekly Report: Recommendations and Reports, 61(RR-4), 1–32.
10. Kondili, L. A., Andreoni, M., Alberti, A., et al. (2021). Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression. Epidemics, 34, 100442.
11. Lara-Paez, G., Zuazo, M., Blumenthal, J., Coyne, C. J., & Hoe nigl, M. (2021). HIV and Hepatitis C virus screening in the emergency department and linkage to care during COVID-19: Challenges and solutions. Journal of Acquired Immune Deficiency Syndromes, 88(2), e14–e16.
12. Kondili, L. A., Aghemo, A., & Andreoni, M. (2021). Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: Need for a Regional programmatic approach on screening and linkage to care. Commentary. Ann Ist Super Sanita, 57(3), 201–204.
13. Marcellusi, A., Simonelli, C., Mennini, F. S., Kondili, L. A., PITER Collaborating Group available at http://www.progettoper.it. (2022). Economic consequences of anti-HCV treatment of
14. Kondili, L. A. (2021). How could Italy reach the HCV elimination by 2030? *Le Infezioni in Medicina*, 29(2), 297–298.
15. Kondili, L. A., Marcellusi, A., Ryder, S., & Craxi, A. (2020). Will the COVID-19 pandemic affect HCV disease burden? *Digestive and Liver Disease*, 52(9), 947–949.
16. Testo della Legge 165 del 27/05/1991.
17. Sagnelli, C., Pisaturo, M., Curatolo, C., Codella, A. V., Coppola, N., & Sagnelli, E. (2021). Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic. *World Journal of Gastroenterology*, 27(42), 7271–7284.
18. Toy, M., Hutton, D., Harris, A. M., Nelson, N., Salomon, J. A., & So, S. (2022). Cost-effectiveness of 1-time universal screening for chronic hepatitis B infection in adults in the United States. *Clinical Infectious Diseases*, 74(2), 210–217.
19. Pawłowska, M., Flisiak, R., Gil, L., et al. (2019). Prophylaxis of hepatitis B virus (HBV) infection reactivation—recommendations of the Working Group for prevention of HBV reactivation. *Clinical and Experimental Hepatology*, 5(3), 195–202.
20. Perrillo, R. P., Gish, R., & Falck-Ytter, Y. T. (2015). American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. *Gastroenterology*, 148(1), 221-244.e3.
21. Campbell, C., Andersson, M. I., Ansari, M. A., et al. (2021). Risk of reactivation of HEPATITIS B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following tocilizumab therapy: A systematic review to inform risk assessment in the COVID-19 Era. *Frontiers in Medicine*, 8, 706482.
22. Rodríguez-Tajes, S., Miralpeix, A., Costa, J., et al. (2021). Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. *Journal of Viral Hepatitis*, 28(1), 89–94.
23. Mori, S., & Fujiyama, S. (2015). Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations. *World Journal of Gastroenterology*, 21(36), 10274–10289.
24. Stasi, C., Tiengo, G., Sadalla, S., & Zignego, A. L. (2021). Treatment or prophylaxis against hepatitis B virus infection in patients with rheumatic disease undergoing immunosuppressive therapy: An update. *Journal of Clinical Medicine*, 10(12), 2564.
25. Gandhi, R. T., Malani, P. N., & Del Rio, C. (2022). COVID-19 Therapeutics for nonhospitalized patients. *JAMA*, 327(7), 617–618.
26. Blach, S., Kondili, L. A., Aghemo, A., et al. (2021). Impact of COVID-19 on global HCV elimination efforts. *Journal of Hepatology*, 74(1), 31–36.
27. Merican, I., Guan, R., Amarapuka, D., et al. (2020). Chronic hepatitis B virus infection in Asian countries. *Journal of Gastroenterology and Hepatology*, 15(12), 1356–1361.
28. The burden of viral hepatitis in the WHO Region of Africa. 2019. Retrieved from https://www.openaccessgovernment.org/viral-hepatitis/67856/.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.